Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial

被引：368

作者：

Yusuf, S. ^{[1
]}

Haridas, K. K. ^{[1
]}

Iyengar, S. S. ^{[1
]}

Jaison, T. M. ^{[1
]}

Joshi, P. ^{[1
]}

Kerkar, P. ^{[1
]}

Naik, S. ^{[1
]}

Prabhakaran, D. ^{[1
]}

Thanikachalam, S. ^{[1
]}

Thomas, N. ^{[1
]}

Parwani, J. ^{[1
]}

Maseeh, A. ^{[1
]}

Srinivasulu, B. ^{[1
]}

Srinivas, J. ^{[1
]}

Rangadham, K. ^{[1
]}

Rayadurgee, N. M. ^{[1
]}

Balaji, Y. ^{[1
]}

Bhavishya, Y. ^{[1
]}

Parikh, K. ^{[1
]}

Chag, M. ^{[1
]}

Shah, U. ^{[1
]}

Joseph, J. J. J. ^{[1
]}

Nesaraj, K. J. ^{[1
]}

Malarvizhi, V. ^{[1
]}

Patil, C. B. ^{[1
]}

Bantwal, G. ^{[1
]}

Nagesh, H. ^{[1
]}

Santosh, M. I. ^{[1
]}

Dwivedi, S. ^{[1
]}

Ramesh, S. S. ^{[1
]}

Suresh, S. ^{[1
]}

Ayyar, V. ^{[1
]}

Rana, P. ^{[1
]}

Tumari, D. P. ^{[1
]}

Agarwal, N. B. ^{[1
]}

Deshpande, N. ^{[1
]}

Bhagchandani, R. ^{[1
]}

Bhagchandani, S. ^{[1
]}

Gupta, B. K. ^{[1
]}

Agarwal, D. K. ^{[1
]}

Panwar, R. B. ^{[1
]}

Bindu, A. V. ^{[1
]}

Alexander, K. G. ^{[1
]}

Pradeep, R. ^{[1
]}

Nambiar, A. ^{[1
]}

Das, C. K. ^{[1
]}

Ramu, M. ^{[1
]}

Nayar, P. ^{[1
]}

Poongothai, S. ^{[1
]}

Mohan, V. ^{[1
]}

机构：

[1] Hamilton Hlth Sci & McMaster Univ, Populat Hlth Res Inst, Hamilton, ON L8L 2X2, Canada

来源：

LANCET | 2009年 / 373卷 / 9672期

关键词：

MYOCARDIAL-INFARCTION; VASCULAR-DISEASE; METAANALYSIS; CHOLESTEROL; STATINS; STROKE;

D O I：

10.1016/S0140-6736(09)60611-5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background The combination of three blood-pressure-lowering drugs at low doses, with a statin, aspirin, and folic acid (the polypill), could reduce cardiovascular events by more than 80% in healthy individuals. We examined the effect of the Polycap on blood pressure, lipids, heart rate, and urinary thromboxane 132, and assessed its tolerability. Methods In a double-blind trial in 50 centres in India, 2053 individuals without cardiovascular disease, aged 45-80 years, and with one risk factor were randomly assigned, by a central secure website, to the Polycap (n=412) consisting of low doses of thiazide (12.5 mg), atenolol (50 mg), ramipril (5 mg), simvastatin (20 mg), and aspirin (100 mg) per day; or to eight other groups, each with about 200 individuals, of aspirin alone, simvastatin alone, hydrochlorthiazide alone, three combinations of the two blood-pressure-lowering drugs, three blood-pressure-lowering drugs alone, or three blood-pressure-lowering drugs plus aspirin. The primary outcomes were LDL for the effect of lipids, blood pressure for antihypertensive drugs, heart rate for the effects of atenolol, urinary 11-dehydrothromboxane B2 for the antiplatelet effects of aspirin, and rates of discontinuation of drugs for safety. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00443794. Findings Compared with groups not receiving blood-pressure-lowering drugs, the Polycap reduced systolic blood pressure by 7.4 mm Hg (95% CI 6.1-8.1) and diastolic blood pressure by 5.6 mm Hg (4.7-6.4), which was similar when three blood-pressure-lowering drugs were used, with or without aspirin. Reductions in blood pressure increased with the number of drugs used (2.2/1.3 mm Hg with one drug, 4.7/3.6 mm Hg with two drugs, and 6.3/4.5 mm Hg with three drugs). Polycap reduced LDL cholesterol by 0.70 mmol/L (95% CI 0.62-0.78),which was less than that with simvastatin alone (0.83 mmol/L, 0.72-0.93; p=0.04); both reductions were greater than for groups without simvastatin (p<0.0001). The reductions in heart rate with Polycap and other groups using atenolol were similar (7.0 beats per min), and both were significantly greater than that in groups without atenolol (p<0.0001). The reductions in 11-dehydrothromboxane B2 were similar with the Polycap (283.1 ng/mmol creatinine, 95% CI 229.1-337.0) compared with the three blood. p res sure-lowering drugs plus aspirin (350.0 ng/mmol creatinine, 294.6-404.0), and aspirin alone (348.8 ng/mmol creatinine, 277.6-419.9) compared with groups without aspirin. Tolerability of the Polycap was similar to that of other treatments, with no evidence of increasing intolerability with increasing number of active components in one pill. Interpretation This Polycap formulation could be conveniently used to reduce multiple risk factors and cardiovascular risk. Funding Cadila Pharmaceuticals, Ahmedabad, India.

引用

页码：1341 / 1351

页数：11

共 10 条

[1]

Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71

[2] Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].

Baigent, C ;

Keech, A ;

Kearney, PM ;

Blackwell, L ;

Buck, G ;

Pollicino, C ;

Kirby, A ;

Sourjina, T ;

Peto, R ;

Collins, R ;

Simes, J .

LANCET, 2005, 366 (9493) :1267-1278

[3] Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials [J].

Law, MR ;

Wald, NJ ;

Morris, JK ;

Jordan, RE .

BMJ-BRITISH MEDICAL JOURNAL, 2003, 326 (7404) :1427-1431

[4] Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis [J].

Law, MR ;

Wald, NJ ;

Rudnicka, AR .

BRITISH MEDICAL JOURNAL, 2003, 326 (7404) :1423-1427

[5]

Lonn E, 2006, NEW ENGL J MED, V354, P1567, DOI 10.1056/NEJMoa060900

[6] A strategy to reduce cardiovascular disease by more than 80% [J].

Wald, NJ ;

Law, MR .

BMJ-BRITISH MEDICAL JOURNAL, 2003, 326 (7404) :1419-1423

[7] The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study [J].

Xavier, Denis ;

Pais, Prem ;

Sigamani, Alben ;

Pogue, Janice ;

Afzal, Rizwan ;

Yusuf, Salim .

NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2009, 6 (02) :96-97

[8] BETA-BLOCKADE DURING AND AFTER MYOCARDIAL-INFARCTION - AN OVERVIEW OF THE RANDOMIZED TRIALS [J].

YUSUF, S ;

PETO, R ;

LEWIS, J ;

COLLINS, R ;

SLEIGHT, P .

PROGRESS IN CARDIOVASCULAR DISEASES, 1985, 27 (05) :335-371

[9] Two decades of progress in preventing vascular disease [J].

Yusuf, S .

LANCET, 2002, 360 (9326) :2-3

[10]

Yusuf S, 2000, NEW ENGL J MED, V342, P145

← 1 →